Search research articles
Contact Us
Filters
Showing results (31-40 of 59) with videos related to
Page
of 6
Sort By:
British Journal of Cancer
|
November 6, 2025
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): cost-effectiveness and budget impact analysis
Paola Cocco, Chris Bojke, Claire Hulme, et al.
Breast Cancer Research and Treatment
|
September 18, 2022
Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009-2016: a cross-sectional study
Anushri Chitkara, Ines Mesa-Eguiagaray, Sarah H Wild, et al.
Advances in Therapy
|
April 8, 2025
A Cost-Effectiveness Analysis of Abemaciclib in Combination with Adjuvant Endocrine Therapy for HR+, HER2-, Node-Positive, High-Risk Early Breast Cancer
Alison Davie, Sory Traoré, Waleed Badreldin, et al.
Breast Cancer Research and Treatment
|
June 1, 2022
Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype
Ines Mesa-Eguiagaray, Sarah H Wild, Sheila M Bird, et al.
International Journal of Population Data Science
|
February 1, 2023
Variation in hospital cost trajectories at the end of life by age, multimorbidity and cancer type
Katharina Diernberger, Xhyljeta Luta, Joanna Bowden, et al.
The Oncologist
|
June 9, 2017
Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis
Daniel A Goldstein, Qiushi Chen, Turgay Ayer, et al.
Breast Cancer Research : BCR
|
April 23, 2025
Breast cancer-specific survival by molecular subtype in different age groups of women in Scotland
Ines Mesa-Eguiagaray, Sarah H Wild, Linda J Williams, et al.
British Journal of Cancer
|
April 24, 2026
Modelled impact of a multi-cancer early detection screening programme on cancer treatment in England
Libby Ellis, Charlotte Eversfield, Ewan Gray, et al.
European Urology
|
March 27, 2018
Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
Michal Sarfaty, Peter S Hall, Kelvin K W Chan, et al.
British Journal of Cancer
|
June 20, 2020
Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data
Ines Mesa-Eguiagaray, Sarah H Wild, Philip S Rosenberg, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 59) with videos related to
Sort By:
Page
of 6
British Journal of Cancer
|
November 6, 2025
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): cost-effectiveness and budget impact analysis
Paola Cocco, Chris Bojke, Claire Hulme, et al.
Breast Cancer Research and Treatment
|
September 18, 2022
Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009-2016: a cross-sectional study
Anushri Chitkara, Ines Mesa-Eguiagaray, Sarah H Wild, et al.
Advances in Therapy
|
April 8, 2025
A Cost-Effectiveness Analysis of Abemaciclib in Combination with Adjuvant Endocrine Therapy for HR+, HER2-, Node-Positive, High-Risk Early Breast Cancer
Alison Davie, Sory Traoré, Waleed Badreldin, et al.
Breast Cancer Research and Treatment
|
June 1, 2022
Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype
Ines Mesa-Eguiagaray, Sarah H Wild, Sheila M Bird, et al.
International Journal of Population Data Science
|
February 1, 2023
Variation in hospital cost trajectories at the end of life by age, multimorbidity and cancer type
Katharina Diernberger, Xhyljeta Luta, Joanna Bowden, et al.
The Oncologist
|
June 9, 2017
Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis
Daniel A Goldstein, Qiushi Chen, Turgay Ayer, et al.
Breast Cancer Research : BCR
|
April 23, 2025
Breast cancer-specific survival by molecular subtype in different age groups of women in Scotland
Ines Mesa-Eguiagaray, Sarah H Wild, Linda J Williams, et al.
British Journal of Cancer
|
April 24, 2026
Modelled impact of a multi-cancer early detection screening programme on cancer treatment in England
Libby Ellis, Charlotte Eversfield, Ewan Gray, et al.
European Urology
|
March 27, 2018
Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
Michal Sarfaty, Peter S Hall, Kelvin K W Chan, et al.
British Journal of Cancer
|
June 20, 2020
Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data
Ines Mesa-Eguiagaray, Sarah H Wild, Philip S Rosenberg, et al.
Page
of 6